BACKGROUND: A growing proportion of patients on antiretroviral therapy in resource-limited settings have switched to second-line regimens. We carried out a systematic review in order to summarize reported rates and reasons for virological failure among people on second-line therapy in resource-limited settings. METHODS: Two reviewers independently searched four databases and three conference websites. Full text articles were screened and data extracted using a standardized data extraction form. RESULTS: We retrieved 5812 citations, of which 19 studies reporting second-line failure rates in 2035 patients across low-income and middle-income countries were eligible for inclusion. The cumulative pooled proportion of adult patients failing virologically was 21.8, 23.1, 26.7 and 38.0% at 6, 12, 24 and 36 months, respectively. Most studies did not report adequate information to allow discrimination between drug resistance and poor adherence as reasons for virological failure, but for those that did poor adherence appeared to be the main driver of virological failure. Mortality on second-line was low across all time points. CONCLUSION: Rates of virological failure on second-line therapy are high in resource-limited settings and associated with duration of exposure to previous drug regimens and poor adherence. The main concern appears to be poor adherence, rather than drug resistance, from the limited number of studies accessing both factors. Access to treatment options beyond second-line remains limited and, therefore, a cause for a concern for those patients in whom drug resistance is the identified cause of virological failure.
BACKGROUND: A growing proportion of patients on antiretroviral therapy in resource-limited settings have switched to second-line regimens. We carried out a systematic review in order to summarize reported rates and reasons for virological failure among people on second-line therapy in resource-limited settings. METHODS: Two reviewers independently searched four databases and three conference websites. Full text articles were screened and data extracted using a standardized data extraction form. RESULTS: We retrieved 5812 citations, of which 19 studies reporting second-line failure rates in 2035 patients across low-income and middle-income countries were eligible for inclusion. The cumulative pooled proportion of adult patients failing virologically was 21.8, 23.1, 26.7 and 38.0% at 6, 12, 24 and 36 months, respectively. Most studies did not report adequate information to allow discrimination between drug resistance and poor adherence as reasons for virological failure, but for those that did poor adherence appeared to be the main driver of virological failure. Mortality on second-line was low across all time points. CONCLUSION: Rates of virological failure on second-line therapy are high in resource-limited settings and associated with duration of exposure to previous drug regimens and poor adherence. The main concern appears to be poor adherence, rather than drug resistance, from the limited number of studies accessing both factors. Access to treatment options beyond second-line remains limited and, therefore, a cause for a concern for those patients in whom drug resistance is the identified cause of virological failure.
Authors: Vinie Kouamou; Justen Manasa; David Katzenstein; Alan M McGregor; Chiratidzo E Ndhlovu; Azure T Makadzange Journal: AIDS Date: 2019-09-01 Impact factor: 4.177
Authors: Mina C Hosseinipour; Ravindra K Gupta; Gert Van Zyl; Joseph J Eron; Jean B Nachega Journal: J Infect Dis Date: 2013-06-15 Impact factor: 5.226
Authors: Julia K Rohr; Prudence Ive; Charles Robert Horsburgh; Rebecca Berhanu; Christopher J Hoffmann; Robin Wood; Andrew Boulle; Janet Giddy; Hans Prozesky; Michael Vinikoor; Mwanza Wa Mwanza; Gilles Wandeler; Mary-Ann Davies; Matthew P Fox Journal: J Acquir Immune Defic Syndr Date: 2018-04-01 Impact factor: 3.731
Authors: Meredith G Warshaw; Vincent J Carey; Elizabeth J McFarland; Liza Dawson; Elaine Abrams; Ann Melvin; Lee Fairlie; Hans Spiegel; Jonathan Jay; Allison L Agwu Journal: Clin Trials Date: 2017-01-31 Impact factor: 2.486
Authors: Denise Evans; Sara Dahlberg; Rebecca Berhanu; Tembeka Sineke; Caroline Govathson; Ingrid Jonker; Elisabet Lönnermark; Matthew P Fox Journal: AIDS Care Date: 2018-02-21